Blood group antigen A and flow cytometric analysis in resected early-stage non-small cell lung cancer

Clinical Cancer Research

Volumn 3, Issue 1, 1997, Pages 87-93

  Graziano, Stephen L ^a   Tatum, Arthur H ^a   Gonchoroff, Nick J ^a   Newman, Nancy B ^a   Kohman, Leslie J ^a  

^a SYRACUSE VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD GROUP A; BLOOD GROUP AB; CELL CYCLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME;

ABO BLOOD-GROUP SYSTEM; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLOW CYTOMETRY; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0031041776     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer Statistics, 1996. CA Cancer J. Clin., 46: 5-27, 1996.
2. Minna, J. D., Higgins, G. A., and Glatstein, E. J. Cancer of the lung. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology (Ed. 3), Philadelphia: J. B. Lippincott Co., 1989, pp. 591-705.
3. Gail, M. H., Eagan, R. T., Feld, R., Ginsberg, R., Goodell, B., Hill, L., Holmes, E. C., Lukeman, J. M., Mountain, C. F., Oldham, R. K., Pearson, F. G., Wright, P. W., Lake, W. H., and the Lung Cancer Study Group. Prognostic factors in patients with resected stage I non-small cell lung cancer: a report from the Lung Cancer Study Group. Cancer (Phila.), 54: 1802-1813, 1984.
4. Lipford, E. H., Eggleston, J. C., Lillemoe, K. D., Sears, D. L., Moore, G. W., and Baker, R. R. Prognostic factors in surgically resected limited-stage, nonsmall cell carcinoma of the lung. Am. J. Surg. Pathol., 8: 357-365, 1984.
5. Takise, A., Tetsuro, K., Shimosato, Y., Watanabe, S., and Suemasu, K. Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2 cm in diameter. Cancer (Phila.), 61: 2083-2088, 1988.
6. Linnoila, R. I., Ruckdeschel, J. C., Piantadosi, S., Jensen, S. M., and Mulshine, J. L. The impact of neuroendocrine (NE) and epithelial (EPI) differentiation on recurrence and survival in patients (pts) with resected non-small cell lung cancer (NSCLC): the LCSG experience. Proc. Am. Soc. Clin. Oncol., 10: 248, 1991.
7. Graziano, S. L., Tatum, A. H., Newman, N. B., Oler, A., Kohman, L. J., Veit, L. J., Gamble, G. P., Coleman, M. J., Barmada, S., and O'Lear, S. The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II nonsmall cell lung cancer. Cancer Res., 54: 2908-2913, 1994.
8. Isobe, H., Miyamoto, H., Shimizu, T., Haneda, H., Hashimoto, M., Inoue, K., Mizuno, S., and Kawakami, Y. Prognostic and therapeutic significance of the flow cytometric nuclear DNA content in non-small cell lung cancer. Cancer (Phila.), 65: 1391-1395, 1990.
9. Zimmerman, P. V., Bint, M. H., Hawson, G. A. T., and Parsons, P. G. Ploidy as a prognostic determinant in surgically treated lung cancer. Lancet, 8558: 530-533, 1987.
10. Slebos, R. J. C., Kibbelaar, R. E., Dalesio, O., Kooistra, A., Stam, J., Meijer, C. J. L. M., Wagenaar, S. S., Vanderschueuren, R. G. J. R. A., Van Zandwijk, N., Mooi, W. J., Bos, J. L., and Rodenhuis, S. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N. Engl. J. Med., 323: 561-565, 1990.
11. Harada, M., Dosaka-Akita, H., Miyamoto, H., Kuzumaki, N., and Kawakami, Y. Prognostic significance of the expression of ras oncogene product in non-small cell lung cancer. Cancer (Phila.), 69: 72-77, 1992.
12. Horio, Y., Takahashi, T., Kuroishi, T., Hibi, K., Suyama, M., Niimi, T., Shimokata, K., Yamakawa, K., Nakamura, Y., Ueda, R., and Takahashi, T. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res., 53: 1-4, 1993.
13. neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res., 50: 5184-5191, 1990.
14. Pezzella, F., Turley, H., Kuzu, I., Tungekar, M. F., Dunnill, M. S., Pierce, C. B., Harris, A., Gatter, K. C., and Mason, D. Y. bcl-2 protein in non-small-cell lung carcinoma. N. Engl. J. Med., 329: 690-694, 1993.
15. Kay, H. E. M., and Wallace, D. M. A and B antigens of tumors arising from urinary epithelium. J. Natl. Cancer Inst., 26: 1349-1365, 1961.
16. Limas, C., Lange, P., Fraley, E. E., and Vessella, R. L. A, B, H antigens in transitional cell tumors of the urinary bladder. Cancer (Phila.), 44: 2099-2107, 1979.
17. Lee, J. S., Ro, J. Y., Sahin, A. A., Hong, W. K., Brown, B. W., Mountain, C. F., and Hittleman, W. N. Expression of blood-group antigen A: a favorable prognostic factor in non-small cell lung cancer. N. Engl. J. Med., 324: 1084-1090, 1991.
18. b antigens with survival in patients with carcinoma of the lung. N. Engl. J. Med., 327: 14-18, 1992.
19. Lee, J. S., and Hong, W. K. Prognostic factors in lung cancer. N. Engl. J. Med., 327: 47-48, 1992.
20. Sahin, A. A., Ro, J. Y., El-Naggar, A. K., Lee, J. S., Ayala, A. G., Teague, K., and Hong, W. H. Flow cytometric analysis of the DNA content of non-small cell lung cancer: ploidy as a significant prognostic indicator in squamous cell carcinoma of the lung. Cancer (Phila.), 65: 530-537, 1990.
21. Ichinose, Y., Hara, N., Ohta, M., Yano, T., Maeda, K., Asoh, H., and Katsuda, Y. Is T factor of the TNM staging system a predominant prognostic factor in pathological stage I non-small-cell lung cancer? J. Thorac. Cardiovasc. Surg., 106: 90-94, 1993.
22. Dazzi, H., Thatcher, H., Hasleton, P. S., and Swindell, R. DNA analysis by flow cytometry in nonsmall cell lung cancer: relationship to epidermal growth factor receptor, histology, tumour stage and survival. Respir. Med., 84: 217-223, 1990.
23. Volm, M., Hahn, E. W., Mattern, J., Muller, T. Vogt-Moykopf, I., and Weber, E. Five-year follow-up study of independent clinical and flow cytometric prognostic factors for the survival of patients with non-small cell lung carcinoma. Cancer Res., 48: 2923-2928, 1988.
24. Filderman, A. E., Silvestri, G. A., Gatsonis, C., Luthringer, D. J., Honig, J., and Flynn, S. D. Prognostic significance of tumor proliferative fraction and DNA content in stage I non-small cell lung cancer. Am. Rev. Respir. Dis., 146: 707-710, 1992.
25. Ten Velde, G. P. M., Schutte, B., Vermeulen, A., Volovics, A., Reynders, M. M. J., and Blijham, G. H. Flow cytometric analysis of DNA ploidy level in paraffin-embedded tissue of non-small-cell lung cancer. Eur. J. Cancer Clin. Oncol., 24: 445-460, 1988.
26. Schmidt, R. A., Rusch, V. W., and Piantadosi, S. A flow cytometric study of non-small cell lung cancer classified as T1N0M0. Cancer (Phila.), 69: 78-85, 1992.
27. Van Bodegom, P. C., Baak, J. P. A., Stroet-Van Galen, C., Schipper, N. W., Wisse-Brekelmans, E. C. M., Vanderschueren, R. G. J. R. A., and Wagenaar, S. S. C. The percentage of aneuploid cells is significantly correlated with survival in accurately staged patients with stage I resected squamous cell lung cancer and long-term follow-up. Cancer (Phila.), 63: 143-147, 1989.
28. Cibas, E. S., Melamed, M. R., Zaman, M. B., and Kimmel, M. The effect of tumor size and tumor cell DNA content on the survival of patients with stage I adenocarcinoma of the lung. Cancer (Phila.), 63: 1552-1556, 1989.
29. Rice, T. W., Bauer, T. W., Gephardt, G. N., Medendorp, S. V., McLain, D. A., and Kirby, T. J. Prognostic significance of flow cytometry in non-small-cell lung cancer. J. Thorac. Cardiovasc. Surg., 106: 210-217, 1993.
30. Mountain, C. F. Prognostic implications of the international staging system for lung cancer. Semin. Oncol., 15: 236-245, 1988.
31. Kreyberg, L., Liebow, A. A., and Uehlinger, E. A. Histological Typing of Lung Tumours, p. 27. Geneva: WHO, 1967.
32. Kreyberg, L. Histological lung cancer types. Acta Pathol. Microbiol. Scand., (Suppl. 157): 14-92, 1962.
33. Hsu, S. M., Raine, L., and Fanger, H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques. J. Histochem. Cytochem., 29: 577-580, 1981.
34. Hedley, D., Friedlander, M., Taylor, I., Rugg, C. A., and Musgrove, E. A. Method for analysis of cellular DNA content of paraffin-embed ded pathological material using flow cytometry. J. Histochem. Cytochem., 31: 1333-1335, 1983.
35. Vindelov, L. V. Flow microfluorometric analysis of nuclear DNA in cells from solid tumors and cell suspensions. Virchows Arch. B Cell Pathol., 24: 227-242, 1977.
36. Witzig, T. E., Loprinzi, C. L., Gonchoroff, N. J., Reiman, H. M., Cha, S. S., Wieand, H. S., Katzmann, J. A., Paulsen J. K., and Moertel, C. G. DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma. Cancer (Phila.), 68: 879-888, 1991.
37. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
38. Lee, E. T. Statistical Models For Survival Data Analysis. Belmont, CA: Life-Time Learning Publications, 1980.
39. Procedure for proportional hazard regression. SAS Institute, Inc., Version 6.09. Cary, NC:, SAS Institute, Inc., 1988.
40. Cox, D. R., and Oakes, D. Analysis of Survival Data. London: Chapman and Hall, Inc., 1984.
41. Rice, T. W., Tubbs, R. R., Hoeltge, G. A., Kirby, T. J., Meeker, D. P., Medendorp, S. V., and Bukowski, R. M. Expression of blood group antigen A by stage I non-small cell lung carcinomas. Ann. Thorac. Surg., 59: 568-572, 1995.
42. Dresler, C. M., Ritter, J. H., Wick, M. R., Roper, C. L., Patterson, G. A., and Cooper, J. D. Immunostains for blood group antigens lack prognostic significance in T1 lung carcinoma, Ann. Thorac. Surg., 59: 1069-1073, 1995.
43. Davidsohn, I., and Ni, L. Y. Loss of isoantigens A. B. and H in carcinoma of the lung. Am. J. Pathol., 57: 307-334, 1969.
44. Orntoft, T. F., Nielsen, M. J. S., Wolf, H., Olsen, S., Clausen, H., Hakomori, S. I., and Dabelsteen, E. Blood group ABO and Lewis antigen expression during neoplastic progression of human urothelium. Cancer (Phila.), 60: 2641-2648, 1987.
45. Dabelsteen, E., Vedtofte, P., Hakomori, S., and Young, W. W. Accumulation of a blood group antigen precursor in oral premalignant lesions. Cancer Res., 43: 1451-1454, 1983.
46. Orntoft, T. F., Wolf, H., Clausen, H., Dabelsteen, E., and Hakomori, S. I. Blood group ANH-related antigens in normal and malignant bladder urothelium: possible structural basis for the deletion of type-2 chain ABH antigens in invasive carcinomas. Int. J. Cancer, 43: 774-780, 1989.
47. Dabelsteen, E., and Fejerskov, O. Loss of epithelial blood group antigen-A during would healing in oral mucous membrane. Acta Pathol. Microbiol. Scand. Sect. A Pathol., 82: 431-444, 1974.
48. MacKenzie, I. C., Dabelsteen, E., and Zimmerman, K. The relationship between expression of epithelial B-like blood group antigen, cell movement and Pathol. Microbiol. Scand. Sect. A Pathol., 85: 49-56, 1977.
49. Miyake, M., Zenita, K., Tanaka, O., Okada, Y., and Kannagi, R. Stage-specific expression of SSEA-1 -related antigens in the developing lung of human embryos and its relation to the distribution of these antigens in lung cancers. Cancer Res., 48: 7150-7158, 1988.
50. Calhoun, L., and Petz, L. D. Erythrocyte antigens and antibodies. In: E. Beutler, M. A. Lichtman, B. S. Coller, and T. J. Kipps (eds.), Williams Hematology, Ed. 5, pp 1595-1610. New York: McGraw-Hill, Inc., 1995.